Forbes William P
Forbes William P's purchase track record
How the stock did after each of Forbes William P's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/16/2023 | HRTX | $74K | +213.0% | +250.0% | +17.5% |
| 3/31/2023 | XAIR | $33K | -36.9% | -65.8% | +4.3% |
| 3/17/2023 | XAIR | $32K | -5.9% | -53.4% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Beyond Air Affirms FY2027 Sales Guidance at $16‑18M. Beyond Air Inc. (XAIR) confirmed its FY2027 sales guidance at $16‑18 million, matching the $16.715 million estimate from analysts. The company also reported preliminary Q2 revenue of about $2.3 million and reiterated the same FY2026 revenue range of $16‑18 million. These updates suggest the firm is on track to meet its projected sales targets for the next few years.
Transaction History
| HRTX | ▲ Buy | Option Exercise | 11,694 | — | 7/31/2026 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 3,326 | $2K | 7/31/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 11,769 | — | 7/30/2026 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 3,348 | $2K | 7/30/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,874 | — | 7/19/2026 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 1,101 | $517 | 7/19/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 12,500 | — | 6/6/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 11,694 | — | 4/30/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 11,770 | — | 4/30/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,874 | — | 4/19/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 11,695 | — | 1/31/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,875 | — | 1/19/2026 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 11,694 | — | 10/31/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,874 | — | 10/19/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 11,695 | — | 7/31/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,874 | — | 7/19/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 12,500 | — | 6/6/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 11,694 | — | 4/30/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,875 | — | 4/19/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,874 | — | 1/19/2025 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,874 | — | 10/19/2024 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,875 | — | 7/19/2024 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 12,500 | — | 6/6/2024 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,874 | — | 4/19/2024 | View on chart |
| HRTX | ▲ Buy | Open Market | 25,000 | $27K | 11/17/2023 | View on chart |
| HRTX | ▲ Buy | Open Market | 50,000 | $47K | 11/16/2023 | View on chart |
| XAIR | ▲ Buy | Open Market | 5,000 | $33K | 3/31/2023 | View on chart |
| XAIR | ▲ Buy | Open Market | 5,000 | $32K | 3/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal
Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.